Your browser doesn't support javascript.
loading
2019 European guideline on the management of lymphogranuloma venereum.
de Vries, H J C; de Barbeyrac, B; de Vrieze, N H N; Viset, J D; White, J A; Vall-Mayans, M; Unemo, M.
Afiliación
  • de Vries HJC; STI Outpatient Clinic, Infectious Diseases Department, Public Health Service Amsterdam, Amsterdam, The Netherlands.
  • de Barbeyrac B; Department of Dermatology, Amsterdam Institute for Infection and Immunity (AI&II), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • de Vrieze NHN; Mycoplasmal and Chlamydial Infections in Humans, University of Bordeaux, Bordeaux, France.
  • Viset JD; Mycoplasmal and Chlamydial Infections in Humans, INRA, Bordeaux, France.
  • White JA; Centre Hospitalier Universitaire de Bordeaux, Laboratoire de Bacteriologie, French National Reference Center for Bacterial STIs, Bordeaux, France.
  • Vall-Mayans M; Department of Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Unemo M; Department of Dermatology, Amsterdam Institute for Infection and Immunity (AI&II), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
J Eur Acad Dermatol Venereol ; 33(10): 1821-1828, 2019 Oct.
Article en En | MEDLINE | ID: mdl-31243838
New or important issues in this updated version of the 2013 European guideline on the management of lymphogranuloma venereum (LGV): EPIDEMIOLOGY: Lymphogranuloma venereum continues to be endemic among European men who have sex with men (MSM) since 2003. Lymphogranuloma venereum infections in heterosexuals are extremely rare in Europe, and there is no evidence of transmission of LGV in the European heterosexual population. AETIOLOGY AND TRANSMISSION: Chlamydia trachomatis serovars/genovars L2b and L2 are the causative strains in the majority of cases in Europe. CLINICAL FEATURES: Among MSM, about 25% of the anorectal LGV infections are asymptomatic. Genital infections among MSM are rare; the ratio of genital vs. anorectal LGV infections is 1 in 15. DIAGNOSIS: To diagnose LGV, a sample tested C. trachomatis positive with a commercial nucleic acid amplification test (NAAT) platform should be confirmed with an LGV discriminatory NAAT. TREATMENT: Doxycycline 100 mg twice a day orally for 21 days is the recommended treatment for LGV. This same treatment is recommended also in asymptomatic patients and contacts of LGV patients. If another regimen is used, a test of cure (TOC) must be performed.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfogranuloma Venéreo / Antibacterianos Tipo de estudio: Etiology_studies / Guideline Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfogranuloma Venéreo / Antibacterianos Tipo de estudio: Etiology_studies / Guideline Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido